Esmo.org - SEO Check

Jetzt kostenlos registrieren! PDF Export
Übersicht der SEO Analyse
Metaangaben
100% 
Seitenqualität
47% 
Seitenstruktur
58% 
Verlinkung
11% 
Server
100% 
Externe Faktoren
100% 
SEO Score
Antwortzeit
0,10 s
Dateigröße
340,00 kB
Wörter
4178
Medien
26
Anzahl Links
448 Intern / 36 Extern

To-do Liste mit SEO Optimierungen

Meta-Angaben im HTML

Titel
(Extrem wichtig)
European Society for Medical Oncology
Die Länge des Titels ist optimal. (355 Pixel von maximal 580 Pixel Länge)
Es gibt keine Wortwiederholungen im Titel.
Meta-Description
(Extrem wichtig)
ESMO is Europe’s leading medical oncology society, providing a professional network for its members and working with national societies across Europe.
Die Meta-Description hat eine optimale Länge. (944 Pixel von maximal 1000 Pixel Länge)
Crawlbarkeit
(Extrem wichtig)
Es gibt keine Probleme beim Zugriff auf die Webseite.
Canonical Link
(Wichtig)
https://www.esmo.org/
Die Seite hat einen korrekten Canonical Link.
Sprache
(Wenig wichtig)
Im Text erkannte Sprache: en
Im HTML angegebene Sprache: en-gb
Serverstandort: Vereinigte Staaten von Amerika
Die Sprache wird im HTML Code wie folgt angegeben: en-gb
Alternate/Hreflang Links
(Wenig wichtig)
Die Seite nutzt keine Alternate Links.
Weitere Metatags
(Wenig wichtig)
Es gibt keinen rel next Meta Tag auf der Seite.
Es gibt keinen rel prev Meta Tag auf der Seite.
Domain
(Wenig wichtig)
Die Domain ist keine Subdomain.
Die Länge der Domain ist gut.
Die Domain enthält keine Umlaute.
Seiten URL
(Wenig wichtig)
In der URL wurden keine Parameter entdeckt.
In der URL wurde keine Session ID entdeckt.
Die URL hat nicht zu viele Unterverzeichnisse.
Zeichensatzkodierung
(Wenig wichtig)
Die Angaben zur Zeichensatzkodierung (UTF-8) sind fehlerfrei.
Doctype
(Nice to have)
Die Doctype Angabe HTML 5 ist korrekt angegeben.
Die Doctype Angabe befindet sich an erster Stelle im HTML-Code.
Favicon
(Nice to have)
Das Favoriten Icon (Favicon) ist korrekt verlinkt.

Meta Tags

NameWert
copyrightESMO
authorESMO
keywordsmedical oncology,oncologists,oncology societies,oncology conferences,europe
descriptionESMO is Europe’s leading medical oncology society, providing a professional network for its members and working with national societies across Europe.
generatoreZ Platform powered by Netgen
viewportwidth=device-width, initial-scale=1.0, maximum-scale=1
norton-safeweb-site-verificationn2ygvjh9mxjj82z9-mte778jumy0erkkd7zxsvx7ps8mpqx4avfdqnwqcw9dvfcmta5hjtjeya4vwcgxzq52gv3kdxnunzhimdkkks2zl39icco8x7d45ihmrkklqfc4
facebook-domain-verification3eeragwmlcd46ur5vkwb776r9jtxte
msvalidate.01BDC2955EF05146A4D0BC9BE3E6DF32BD
langen-gb
og:typewebsite
og:titleESMO
og:descriptionESMO
og:imagehttps://www.esmo.org/bundles/app/images/esmo_opengraph.png
charsetutf-8

Analysiere jetzt kostenlos bis zu 1.000 Unterseiten von esmo.org!

Kostenlos Testen
Die Nutzung des Basis Accounts ist zeitlich unbegrenzt möglich

Seitenqualität

Inhalt
(Extrem wichtig)
Der Seiteninhalt ist mit 4178 Wörtern sehr lang. Es macht eventuell Sinn den Text auf mehrere Seiten aufzuteilen.
Es befinden sich 6 Text-Duplikate auf der Seite:
  • Duplikat 1: It is intended for the treatment of adult patients with relapsed or re...
  • Duplikat 2: In the MARIPOSA study, a significant improvement in progression-free s...
  • Duplikat 3: New indication concerns a combination with durvalumab for the maintena...
Die durchschnittliche Satzlänge ist mit 71.88 Wörtern hoch.
Der Text besteht zu 26.3% aus Füllwörtern.
Worte aus dem Titel werden im Text wiederholt.
Wörter aus der H1 Überschrift werden im Text der Seite verwendet.
Im Text befindet sich eine Aufzählung, dies deutet auf eine gute Textstruktur hin.
Es wurden 46 Fließtextblöcke auf der Seite gefunden.
Es wurden keine Platzhalter Texte bzw. Bilder gefunden.
Frames
(Extrem wichtig)
Die Seite hat kein Frameset.
Mobile
(Wenig wichtig)
Es ist kein Apple-Touch Icon angegeben.
Der angegebene Viewport (width=device-width, initial-scale=1.0, maximum-scale=1) ist korrekt.
Bold- und Strongtags
(Wenig wichtig)
Einige der Tags sind zu lang. Mit 118 Zeichen ist dieser länger als 70 Zeichen:
"oops, you're using an old version of your browser so some of the features on this page may not be disp..."
Bilder Optimierung
(Wenig wichtig)
Alle gefundenen Bilder haben Alt-Attribute. (Alternativer Bild Text)
Soziale Vernetzung
(Nice to have)
Es befinden sich wenige Social-Sharing Möglichkeiten auf der Seite. Mit Plugins zum Teilen kann die Reichweite der Seite in sozialen Netzwerken erhöht werden.
Zusätzliches Markup
(Nice to have)
Es wurde kein zusätzliches Markup gefunden.
HTTPS
(Wenig wichtig)
Die Seite verwendet HTTPS um Daten sicher zu übertragen.
Alle eingebundenen Dateien werden ebenfalls über HTTPS ausgeliefert.

Medienliste

URLALT-AttributeTitel
...age/30169140e251db563e46719de7ec91e4.svgESMO
...inoma-esmo-euracan-1000x250-july_i30.jpgESMO-Webinar-Series-Nasopharyngeal-Carcinoma-ESMO-EURACAN-1000x250-July
...tatic-non-small-cell-lung-cancer_i30.jpgESMO-Clinical-Practice-Guidelines-1000x250-Oncogene-Addicted-Metastatic-Non-Small-Cell-Lung-Cancer
...ceptorship-lung-cancer-1000x1000_i30.jpgESMO-Preceptorship-Lung-Cancer-1000x1000
...torship-gastric-cancer-1000x1000_i30.jpgESMO-Preceptorship-Gastric-Cancer-1000x1000
...795-3-eng-GB/esmo-mcbs-1000x1000_i30.jpgESMO-MCBS 1000x1000
...ients-with-the-best-care-options_i30.jpgProvide your patients with the best care options.
...es/4397014-1-eng-GB/esmo-courses_i30.jpgESMO Courses
...-1-eng-GB/esmo-oncology-journals_i30.jpgESMO Oncology Journals
...ns/4396970-1-eng-GB/publications_i30.jpgPublications
...t-course-valencia-2024-1000x1000_i30.jpgESMO-Medical-Student-Course-Valencia-2024-1000x1000
...ptorship-breast-cancer-1000x1000_i30.jpgESMO-Preceptorship-Breast-Cancer-1000x1000
...o-academy-meeting-2024-1000x1000_i30.jpgESMO-Academy-Meeting-2024-1000x1000
...ent-course-naples-2024-1000x1000_i30.jpgESMO-Medical-Student-Course-Naples-2024-1000x1000
...-courses-breast-cancer-1000x1000_i30.jpgESMO-Advanced-Courses-Breast-Cancer-1000x1000
...-GB/esmo-congress-2024-1000x1000_i30.jpgESMO-Congress-2024-1000x1000
...ip-ovarian-cancer-2024-1000x1000_i30.jpgESMO-Preceptorship-Ovarian-Cancer-2024-1000x1000
...torship-gastric-cancer-1000x1000_i30.jpgESMO-Preceptorship-Gastric-Cancer-1000x1000
...lecular-cancer-biology-1000x1000_i30.jpgESMO-Preceptorship-Molecular Cancer Biology-1000x1000
...o-advanced-courses-adc-1000x1000_i30.jpgESMO-Advanced-Courses-ADC-1000x1000
...o-advanced-courses-adc-1000x1000_i30.jpgESMO-Advanced-Courses-ADC-1000x1000
...o-advanced-courses-adc-1000x1000_i30.jpgESMO-Advanced-Courses-ADC-1000x1000
Video-URLBreiteHöhe
https://www.youtube.com/embed/ybpRSarS2TY770433
https://www.youtube.com/embed/iPoTPdElxtU770433
https://www.youtube.com/embed/d1ZiZbh8mOk770433

Seitenstruktur

H1 Überschrift
(Extrem wichtig)
European Society For Medical Oncology
Die H1-Überschrift ist perfekt.
Überschriften
(Wichtig)
Einige Überschriftentexte kommen doppelt auf der Seite vor.
Es befinden sich 100 Überschriften auf der Seite. Die Anzahl der Überschriften sollte in einem besseren Verhältnis zum Text stehen.

Überschriftenstruktur

Überschriften HierarchieInhalt
H1 European Society For Medical Oncology
H2 ESMO Immuno-Oncology Congress 2024
H2 Nasopharyngeal Carcinoma Webinar
H2 ESMO Oncogene-Addicted mNSCLC Living Guideline
H2 ESMO Asia 2024
H2 Molecular Analysis for Precision Oncology Congress 2024
H2 ESMO Preceptorship on Lung Cancer, 15-16 November 2024, Paris, France
H2 ESMO Preceptorship Course on Gastric Cancer, 4-5 December 2024, Singapore
H2 ESMO-MCBS
H2 July ESMO Virtual Plenary
H2 Latest News
H2 Development of T-Cell Lymphoma After Chimeric Antigen Receptor T-Cell Therapy
H2 EMA Recommends Granting a Conditional Marketing Authorisation for Odronextamab
H2 Entrectinib Is Effective and Well Tolerated in Patients with Treatment-Naïve ROS1-positive Advanced/Metastatic NSCLC
H2 FDA Approves Durvalumab with Chemotherapy for Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer
H2 First-line avimantamab plus lazertinib shows efficacy in patients with high-risk EGFR-mutant advanced NSCLC
H2 One Year of Adjuvant T-DM1 Leads to Outstanding Long-Term Outcomes Among Patients with Stage I HER2-positive Breast Cancer
H2 Patient Guide in Bladder Cancer Now Available Also in Greek
H2 EMA Recommends Extension of Therapeutic Indications for Olaparib to Patients with Endometrial Cancer
H2 PET-2-Guided BrECADD Better Tolerated and More Effective than eBEACOPP in Patients with Newly Diagnosed, Advanced-Stage cHL
H2 Development of T-Cell Lymphoma After Chimeric Antigen Receptor T-Cell Therapy Text-Duplikat
H2 EMA Recommends Granting a Conditional Marketing Authorisation for Odronextamab Text-Duplikat
H2 Entrectinib Is Effective and Well Tolerated in Patients with Treatment-Naïve ROS1-positive Advanced/Metastatic NSCLC Text-Duplikat
H2 FDA Approves Durvalumab with Chemotherapy for Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer Text-Duplikat
H2 One Year of Adjuvant T-DM1 Leads to Outstanding Long-Term Outcomes Among Patients with Stage I HER2-positive Breast Cancer Text-Duplikat
H2 EMA Recommends Extension of Therapeutic Indications for Olaparib to Patients with Endometrial Cancer Text-Duplikat
H2 PET-2-Guided BrECADD Better Tolerated and More Effective than eBEACOPP in Patients with Newly Diagnosed, Advanced-Stage cHL Text-Duplikat
H2 FDA Grants Accelerated Approval to Adagrasib with Cetuximab for KRAS G12C-mutated Advanced Colorectal Cancer
H2 Second- or Third-Line Treatment with Tisotumab Vedotin Results in Greater Efficacy than Chemotherapy in Patients with Recurrent Cervical Cancer
H2 Prevention and Early Detection of Gastrointestinal Cancers Take on New Importance Amidst a Younger Population
H2 Cross-Border Network of European Specialists Provides New Treatment Options For Women with Complex Rare Gynaecological Cancers
H2 ESMO Gastrointestinal Cancers Congress 2024 Munich, Germany, 26-29 June
H2 ESMO Gynaecological Cancers Congress 2024, 20-22 June, Florence, Italy
H2 World No Tobacco Day 2024: European Societies call for an EU Endgame on Tobacco
H2 Assisted Reproduction Treatments are Safe in Young Breast Cancer Survivors with High-risk Genes
H2 ESMO Breast Cancer 2024, 15-17 May, Berlin, Germany
H2 European Lung Cancer Congress 2024, 20-23 March, Prague, Czech Republic
H2 ESMO Sarcoma and Rare Cancers Congress 2024, 14-16 March, Lugano, Switzerland
H2 ESMO Calls for Urgent Action at Both EU and National Levels to Safeguard the Future of Oncological Research in Europe
H2 ESMO Journals Have Maintained Strong Impact Factors
H2 New ESMO President 2027-2028 Elected
H2 Three Prominent ESMO Officers Shine in News Pages for Their Accomplishments in Cancer Research
H2 Medical Oncologists Incredulous at the Commission’s Latest Backtracking on the Evaluation of the EU Tobacco Products Directive
H2 2024 ESMO Breast Cancer Award Recipient Announced
H2 2024 Heine H. Hansen Award Recipient Announced
H2 Nomination Process for the 2024 ESMO Society Awards Now Open 
H2 ESMO Committees and Working Groups: New Chair Appointments
H2 First-line avimantamab plus lazertinib shows efficacy in patients with high-risk EGFR-mutant advanced NSCLC Text-Duplikat
H2 Eftilagimod alpha plus pembrolizumab shows promise in HNSCC with negative PD-1 expression
H2 How to interpret genomic testing results? ESMO recommendations to make reports easy to read
H2 Oncologists do not feel well-prepared to address the health needs of LGBTQ cancer patients
H2 Doublet immunotherapy consolidates its role in hepatocellular carcinoma
H2 Ten years of improvement in the treatment of liver cancer
H2 Growing evidence supports the use of ctDNA as a biomarker in colon cancer
H2 Harnessing the power of the gut microbiome in colorectal cancer
H2 Liver transplantation plus chemotherapy prolongs survival in patients with definitively unresectable colorectal liver metastases
H2 Education
H2 Provide your patients with the best care options.
H2 ESMO Courses
H2 ESMO Oncology Journals
H2 Publications
H2 Next Meetings
H2 ESMO Course in Medical Oncology for Medical Students Valencia 2024
H2 ESMO Preceptorship on Breast Cancer 2024: Munich
H2 ESMO Academy 2024
H2 ESMO Course in Medical Oncology for Medical Students Naples 2024
H2 ESMO Advanced Course on Role of CDK4/6 Inhibitors in Hormone Receptor Positive HER2 Negative in Breast Cancer 2024: Jeddah
H2 ESMO Congress 2024
H2 ESMO Preceptorship on Ovarian Cancer 2024: Lisbon
H2 ESMO Preceptorship on Gastric Cancer 2024: Lisbon
H2 ESMO Preceptorship on Practising Oncology: Dealing with Special Strategies, Patient Populations and Toxicities 2024: Lugano
H2 ESMO Advanced Course on ADC Development, Therapeutic Applications and Research: Breast, Gynaecological and GI Cancers 2024: Zurich
H2 ESMO Advanced Course on ADC Development, Therapeutic Applications and Research: Thoracic and GU Cancers 2024: Singapore
H2 ESMO Advanced Course on ADC Development, Therapeutic Applications and Research: Breast, Gynaecological and GI Cancers 2024: Singapore
H2 Video Gallery
H2 ESMO Immuno-Oncology 2024: Congress Experts in the field invite you to share your research.
H2 ESMO Women for Oncology Forum 2023: 10 years of ESMO W4O advocating for gender equity
H2 ESMO Virtual Mentorship Programme
H2 ESMO/ASCO Global Curriculum in Medical Oncology: Insights on the 2023 Edition
H2 ESMO/ASCO Global Curriculum in Medical Oncology: Insights on the 2023 Edition Text-Duplikat
H2 #ESMO24: F. André, R. Dent, M. Garassino, M. Van der Heijden & M. Lambertini invite you to attend
H2 Precision Medicine in Prostate Cancer
H2 ESMO Asia Congress 2024: multidisciplinary oncology in the Asian region
H2 Unlock your future: Why Young Oncologists should attend MAP 2024
H2 Recommendations for the use of NGS in patients with metastatic cancer
H2 Precision oncology experts on why you should submit your abstract for MAP 2024
H2 Why you should submit your abstract for MAP 2024
H2 Career Development
H2 Improve your career path
H2 Are you looking for a fellowship not offered by ESMO or would like to post a fellowship?
H2 ESMO Examination
H2 Thinking of applying for an ESMO Oncology Fellowship?
H2 Become a Member
H3 Membership
H4 172
H4 35k +
H4 40+
H5 Legal
H5 Useful links
H5 Subscribe to ESMO newsletters
Es befinden sich zu viele interne Links (448) auf der Seite.
Einige der Linktexte der internen Links sind zu lang.
Die internen Links haben teilweise dynamische Parameter. Alle internen URLs, welche nicht als nofollow markiert sind, sollten keine dynamischen Parameter aufweisen.
Einige der Linktexte wiederholen sich.
Es gibt 1 Links mit einem trivialem Linktext.
Es befinden sich zu viele externe Links (36) auf der Seite.

Gefundene Links auf dieser Seite

LinkAttributeLinktext
https://www.google.com/chrome/Neues Fenster Extern Subdomain Google Chrome 24+
https://www.mozilla.org/en-US/...Neues Fenster Extern Subdomain Mozilla Firefox 20+
https://www.microsoft.com/en-u...Neues Fenster Extern Subdomain Internet Explorer 11
https://www.opera.com/downloadNeues Fenster Extern Subdomain Opera 15–18
https://www.apple.com/safari/Neues Fenster Extern Subdomain Apple Safari 7
https://www.seamonkey-project....Neues Fenster Extern Subdomain SeaMonkey 2.15-2.23
https://www.esmo.org/Subdomain ESMO
/meeting-calendarSubdomain Meeting Calendar
https://oncologypro.esmo.org/Extern Subdomain OncologyPRO
/membership/join-esmoSubdomain Become a member
https://www.esmo.org/saml/loginLogin
https://www.esmo.org/Subdomain Textduplikat IMG-ALT ESMO
A-TITLE ESMO
/membership/member-benefitsSubdomain Benefits of an ESMO Membership
https://www.esmo.org/about-esmoSubdomain Who we are
/about-esmo/how-we-workSubdomain How we work
/about-esmo/esmo-valuesSubdomain Our values
https://www.esmo.org/Subdomain Textduplikat ESMO
/meeting-calendarSubdomain Textduplikat Meeting Calendar
https://oncologypro.esmo.org/Extern Subdomain Textduplikat OncologyPRO
https://www.esmo.org/about-esmoSubdomain About ESMO
A-TITLE About ESMO
/about-esmo/esmo-vision-2025Subdomain ESMO Vision 2025
/about-esmo/esmo-vision-2025/o...Subdomain One Oncology Community
/about-esmo/esmo-vision-2025/e...Subdomain Education for Life
/about-esmo/esmo-vision-2025/a...Subdomain Accessible Cancer Care
/about-esmo/esmo-missionSubdomain ESMO Mission
/about-esmo/esmo-valuesSubdomain ESMO Values
/about-esmo/awardsSubdomain Awards
/about-esmo/awards/esmo-award-...Subdomain ESMO Award Nominations
/about-esmo/awards/fellow-of-e...Subdomain Fellow of ESMO (FESMO)
/about-esmo/awards/fellow-of-e...Subdomain FESMO 2022
/about-esmo/awards/esmo-awardSubdomain ESMO Award
/about-esmo/awards/esmo-award-...Subdomain ESMO Award for Translational Research
/about-esmo/awards/esmo-women-...Subdomain ESMO Women for Oncology Award
/about-esmo/awards/esmo-lifeti...Subdomain ESMO Lifetime Achievement Award
/about-esmo/awards/esmo-breast...Subdomain ESMO Breast Cancer Award
/about-esmo/awards/heine-h.-ha...Subdomain Heine H. Hansen Award
/about-esmo/awards/esmo-award-...Subdomain ESMO Award for Immuno-Oncology
/about-esmo/awards/tat-honorar...Subdomain TAT Honorary Award
/about-esmo/organisational-str...Subdomain Organisational Structure
/about-esmo/organisational-str...Subdomain ESMO Council
/about-esmo/organisational-str...Subdomain Executive Board
/about-esmo/organisational-str...Subdomain Annals of Oncology Editorial Board
/about-esmo/organisational-str...Subdomain Audit Committee
/about-esmo/organisational-str...Subdomain Cancer Medicines Committee
/about-esmo/organisational-str...Subdomain Compliance Committee
/about-esmo/organisational-str...Subdomain Educational Committee
/about-esmo/organisational-str...Subdomain Adolescents and Young Adults Working Group
/about-esmo/organisational-str...Subdomain Designated Centres Working Group
/about-esmo/organisational-str...Subdomain Educational Publications Working Group
/about-esmo/organisational-str...Subdomain ESMO Faculty
/about-esmo/organisational-str...Subdomain ESMO SIOG Cancer in the Elderly Working Group
/about-esmo/organisational-str...Subdomain Examination & Accreditation Working Group
/about-esmo/organisational-str...Subdomain OncologyPRO Working Group
/about-esmo/organisational-str...Subdomain Practising Oncologists Working Group
/about-esmo/organisational-str...Subdomain Real World Data and Digital Health Working Group
/about-esmo/organisational-str...Subdomain Translational Research and Precision Medicine Working Group
/about-esmo/organisational-str...Subdomain Textduplikat ESMO Faculty
/about-esmo/organisational-str...Subdomain ESMO Open Editorial Board
/about-esmo/organisational-str...Subdomain Guidelines Committee
/about-esmo/organisational-str...Subdomain ESMO-Magnitude of Clinical Benefit Scale Working Group
/about-esmo/organisational-str...Subdomain Major Achievements
/about-esmo/organisational-str...Subdomain IOTECH Editorial Board
/about-esmo/organisational-str...Subdomain Leadership Development Committee
/about-esmo/organisational-str...Subdomain Membership Committee
/about-esmo/organisational-str...Subdomain National Societies Committee
/about-esmo/organisational-str...Subdomain Nomination Committee
/about-esmo/organisational-str...Subdomain Communication Committee
/about-esmo/organisational-str...Subdomain Women for Oncology Committee
/about-esmo/organisational-str...Subdomain Young Oncologists Committee
/about-esmo/organisational-str...Subdomain Textduplikat Major Achievements
/about-esmo/organisational-str...Subdomain ESMO Members: Get Involved
/about-esmo/organisational-str...Subdomain ESMO Committees: Application Form
/about-esmo/organisational-str...Subdomain Editor-in-Chief Of ESMO Rare Cancers
/about-esmo/organisational-str...Subdomain OPWG Open Call for Members
/about-esmo/organisational-str...Subdomain ESMO Task Forces
/about-esmo/organisational-str...Subdomain ESMO Gender Medicine Task Force
/about-esmo/organisational-str...Subdomain Climate Change Task Force
/about-esmo/organisational-str...Subdomain Resilience Task Force
/about-esmo/organisational-str...Subdomain ESMO Clinical Research Observatory Task Force (ECRO)
/about-esmo/how-we-workSubdomain Textduplikat How we work
/about-esmo/how-we-work/declar...Subdomain Declaration of Interest
/about-esmo/how-we-work/declar...Subdomain EFPIA Disclosure Code
/about-esmo/how-we-work/esmo-e...Subdomain ESMO Presidential Election: 2027-2028
/about-esmo/how-we-work/esmo-e...Subdomain ESMO Elections FAQ
/about-esmo/how-we-work/esmo-s...Subdomain ESMO Structure
/about-esmo/how-we-work/code-o...Subdomain Code of Conduct
/about-esmo/how-we-work/esmo-a...Subdomain ESMO Annual Report
/about-esmo/how-we-work/esmo-f...Subdomain ESMO Funding
/about-esmo/how-we-work/esmo-f...Subdomain 2022 Funding Sources
/about-esmo/how-we-work/esmo-f...Subdomain 2019 Funding Sources
/about-esmo/how-we-work/esmo-f...Subdomain 2020 Funding Sources
/about-esmo/how-we-work/esmo-f...Subdomain 2021 Funding Sources
/about-esmo/how-we-work/bylawsSubdomain ESMO Bylaws
/about-esmo/how-we-work/esmo-g...Subdomain General Assembly
/about-esmo/how-we-work/esmo-g...Subdomain Notification of 2023 ESMO General Assembly Vote
/about-esmo/biographiesSubdomain Biographies
/about-esmo/careers-at-esmoSubdomain Careers at ESMO
/about-esmo/discover-esmo-jour...Subdomain Discover ESMO Journals
/about-esmo/discover-esmo-jour...Subdomain Annals of Oncology
/about-esmo/discover-esmo-jour...Subdomain About Annals of Oncology
/about-esmo/discover-esmo-jour...Subdomain ESMO Open
/about-esmo/discover-esmo-jour...Subdomain Frequently Asked Questions
/about-esmo/discover-esmo-jour...Subdomain Immuno-Oncology and Technology
/about-esmo/discover-esmo-jour...Subdomain ESMO Gastrointestinal Oncology
/about-esmo/discover-esmo-jour...Subdomain ESMO Real World Data and Digital Oncology
/about-esmo/discover-esmo-jour...Subdomain ESMO Affiliated Journals
/about-esmo/discover-esmo-jour...Subdomain Cancer Treatment Reviews
/about-esmo/discover-esmo-jour...Subdomain Clinical Lymphoma Myeloma and Leukemia
/about-esmo/discover-esmo-jour...Subdomain Lung Cancer
/about-esmo/discover-esmo-jour...Subdomain The Breast
/about-esmo/discover-esmo-jour...Subdomain COVID-19 and cancer care in the ESMO journals
/about-esmo/esmo-brandSubdomain ESMO Brand
/about-esmo/esmo-brand/esmo-logoSubdomain ESMO Logo
/about-esmo/collaborate-with-esmoSubdomain Collaborate with ESMO
/about-esmo/collaborate-with-e...Subdomain Textduplikat Frequently Asked Questions
/about-esmo/president-letterSubdomain President Letter
/about-esmo/president-letter/s...Subdomain Stepping into the shoes of a Society with a global footprint
/about-esmo/president-letter/e...Subdomain Embracing a year of strong collaboration and steady progress
/about-esmo/joining-forcesSubdomain Joining Forces
/about-esmo/joining-forces/esm...Subdomain ESMO for World Cancer Day 2024
/about-esmo/joining-forces/esm...Subdomain ESMO for World Cancer Day 2023
/about-esmo/joining-forces/esm...Subdomain ESMO for World Cancer Day 2022
/about-esmo/joining-forces/esm...Subdomain ESMO for World Cancer Day 2021
/about-esmo/joining-forces/esm...Subdomain ESMO for World Cancer Day 2020
/about-esmo/contact-usSubdomain Contact Us
https://www.esmo.org/membershipSubdomain Membership
A-TITLE Membership
/membership/join-esmoSubdomain Join ESMO
/membership/member-benefitsSubdomain Member Benefits
/membership/membership-categor...Subdomain Membership Categories & Annual Fees
/membership/esmo-in-your-countrySubdomain ESMO in Your Country
https://www.esmo.org/guidelinesSubdomain Guidelines
A-TITLE Guidelines
/guidelines/guidelines-by-topicSubdomain Guidelines by topic
/guidelines/guidelines-by-topi...Subdomain Breast Cancer
/guidelines/guidelines-by-topi...Subdomain Cancers of Unknown Primary Site
/guidelines/guidelines-by-topi...Subdomain Endocrine and Neuroendocrine Cancers
/guidelines/guidelines-by-topi...Subdomain Gastrointestinal Cancers
/guidelines/guidelines-by-topi...Subdomain Genitourinary Cancers
/guidelines/guidelines-by-topi...Subdomain Gynaecological Cancers
/guidelines/guidelines-by-topi...Subdomain Haematological Malignancies
/guidelines/guidelines-by-topi...Subdomain Head and Neck Cancers
/guidelines/guidelines-by-topi...Subdomain Hereditary Syndromes
/guidelines/guidelines-by-topi...Subdomain Lung and Chest Tumours
/guidelines/guidelines-by-topi...Subdomain Melanoma and Skin Cancers
/guidelines/guidelines-by-topi...Subdomain Neuro-Oncology
/guidelines/guidelines-by-topi...Subdomain Sarcoma and GIST
/guidelines/guidelines-by-topi...Subdomain Supportive and Palliative Care
/guidelines/guidelines-newsSubdomain Guidelines News
/guidelines/esmo-expert-consen...Subdomain ESMO Expert Consensus Statements
/guidelines/pagaSubdomain Pan-Asian Guidelines Adaptation (PAGA)
/guidelines/esmo-guidelines-me...Subdomain ESMO Guidelines Methodology
/guidelines/pocket-guidelines-...Subdomain Pocket Guidelines & Mobile App
/guidelines/pocket-guidelines-...Subdomain Translated ESMO Pocket Guidelines
/guidelines/guidelines-slide-setsSubdomain Guidelines Slide Sets
/guidelines/cancer-patient-man...Subdomain Cancer Patient Management During the COVID-19 Pandemic
/guidelines/cancer-patient-man...Subdomain Disclaimer
/guidelines/cancer-patient-man...Subdomain Primary brain tumours in the COVID-19 era
/guidelines/cancer-patient-man...Subdomain Gastrointestinal cancers: Hepatocellular carcinoma (HCC) in the COVID-19 era
/guidelines/cancer-patient-man...Subdomain Genitourinary cancers: Urothelial cancer of the bladder in the COVID-19 era
/guidelines/cancer-patient-man...Subdomain Genitourinary cancers: Renal cell cancer in the COVID-19 era
/guidelines/cancer-patient-man...Subdomain Genitourinary cancers: Prostate cancer in the COVID-19 era
/guidelines/cancer-patient-man...Subdomain Gynaecological malignancies: Cervical cancer in the COVID-19 era
/guidelines/cancer-patient-man...Subdomain Gynaecological malignancies: Endometrial cancer in the COVID-19 era
/guidelines/cancer-patient-man...Subdomain Haematological malignancies: DLBCL, MCL and Aggressive T-cell lymphoma in the second phase of the COVID-19 pandemic (ESMO-EHA)
/guidelines/cancer-patient-man...Subdomain Haematological malignancies: Hodgkin lymphoma in the second phase of the COVID-19 pandemic (ESMO-EHA)
/guidelines/cancer-patient-man...Subdomain Haematological malignancies: Indolent B-NHL in the second phase of the COVID-19 pandemic (ESMO-EHA)
/guidelines/cancer-patient-man...Subdomain Haematological malignancies: Multiple myeloma in the COVID-19 era
/guidelines/cancer-patient-man...Subdomain Head and neck cancers in the COVID-19 era
/guidelines/cancer-patient-man...Subdomain Melanoma in the COVID-19 era
/guidelines/cancer-patient-man...Subdomain Sarcomas in the COVID-19 era
/guidelines/cancer-patient-man...Subdomain Supportive Care in the COVID-19 era
/guidelines/covid-19-palliativ...Subdomain COVID-19 Palliative Care Pathways
/guidelines/q-a-on-covid-19Subdomain Q&A on COVID-19
/guidelines/covid-19-adapted-r...Subdomain COVID-19 adapted recommendations Slide Sets
/guidelines/esmo-mcbsSubdomain ESMO-MCBS
/guidelines/esmo-mcbs/esmo-mcb...Subdomain ESMO-MCBS in Action
/guidelines/esmo-mcbs/esmo-mcb...Subdomain ESMO-MCBS sessions at ESMO 2020
/guidelines/esmo-mcbs/esmo-mcb...Subdomain ESMO-MCBS Online Tutorials
/guidelines/esmo-mcbs/about-th...Subdomain About the ESMO-MCBS
/guidelines/esmo-mcbs/esmo-mcb...Subdomain ESMO-MCBS Terms of Use
/guidelines/esmo-mcbs/esmo-mcb...Subdomain ESMO-MCBS for Haematological Malignancies
/guidelines/esmo-mcbs/esmo-mcb...Subdomain ESMO-MCBS for Solid Tumours
/about-esmo-meetingsSubdomain Meetings
A-TITLE Meetings
/meeting-calendarSubdomain Textduplikat Meeting Calendar
/meeting-calendar/past-meetingsSubdomain Past Meetings
/about-esmo-meetings/esmo-cong...Subdomain ESMO Congresses
/about-esmo-meetings/esmo-virt...Subdomain ESMO Virtual Plenaries
/about-esmo-meetings/esmo-virt...Subdomain Sponsors
/about-esmo-meetings/esmo-virt...Subdomain Abstracts
/about-esmo-meetings/esmo-virt...Subdomain FAQs
/about-esmo-meetings/esmo-academySubdomain ESMO Academy
/about-esmo-meetings/esmo-adva...Subdomain ESMO Advanced Courses
/about-esmo-meetings/esmo-adva...Subdomain Textduplikat FAQs
/about-esmo-meetings/esmo-adva...Subdomain Acknowledgements
/about-esmo-meetings/esmo-adva...Subdomain Testimonials
/about-esmo-meetings/esmo-prec...Subdomain ESMO Preceptorship Courses
/about-esmo-meetings/esmo-prec...Subdomain Textduplikat Acknowledgements
/about-esmo-meetings/esmo-prec...Subdomain Textduplikat FAQs
/about-esmo-meetings/esmo-prec...Subdomain Textduplikat Testimonials
/about-esmo-meetings/esmo-summitsSubdomain ESMO Summits
/about-esmo-meetings/esmo-summ...Subdomain Textduplikat Testimonials
/about-esmo-meetings/esmo-cour...Subdomain ESMO Courses in Medical Oncology for Medical Students
/about-esmo-meetings/esmo-cour...Subdomain ESMO Best Student Award
/about-esmo-meetings/esmo-cour...Subdomain Textduplikat Testimonials
/about-esmo-meetings/eso-esmo-...Subdomain ESO-ESMO Masterclasses
/about-esmo-meetings/esmo-symp...Subdomain ESMO Symposia
/about-esmo-meetings/esmo-coll...Subdomain ESMO Colloquia
/about-esmo-meetings/esmo-webi...Subdomain ESMO Webinar Series
/about-esmo-meetings/workshops...Subdomain Workshops
/about-esmo-meetings/esmo-even...Subdomain ESMO Events App
/about-esmo-meetings/esmo-even...Subdomain How to Use the App
/about-esmo-meetings/esmo-lice...Subdomain ESMO Licensed Events
/career-developmentSubdomain Career Development
A-TITLE Career development
/career-development/oncology-f...Subdomain Oncology Fellowships
/career-development/oncology-f...Subdomain Host Institutes
/career-development/oncology-f...Subdomain Host an ESMO Fellow
/career-development/oncology-f...Subdomain Fellowship Offers
/career-development/oncology-f...Subdomain Benefits for Institutes
/career-development/oncology-f...Subdomain Awardees and Reports
/career-development/oncology-f...Subdomain External Oncology Fellowship Opportunities
/career-development/oncology-f...Subdomain About Oncology Fellowships
/career-development/resilience...Subdomain Textduplikat Resilience Task Force
/career-development/resilience...Subdomain ESMO Resilience Task Force: Survey Series
/career-development/young-onco...Subdomain Young Oncologists Corner
/career-development/young-onco...Subdomain Young Oncologists Track
/career-development/young-onco...Subdomain YO4YO Virtual Session Series
/career-development/young-onco...Subdomain About Young Oncologists Corner
/career-development/young-onco...Subdomain National Activities
/career-development/young-onco...Subdomain Considering a Career Abroad?
/career-development/esmo-exami...Subdomain ESMO Examination
/career-development/esmo-exami...Subdomain Parallel Sessions
/career-development/esmo-exami...Subdomain Why Sit the ESMO Exam?
/career-development/esmo-exami...Subdomain ESMO Exam Talent Pool
/career-development/esmo-exami...Subdomain Sample Exam Questions Explained
/career-development/esmo-exami...Subdomain Best Exam Award
/career-development/recertific...Subdomain Recertification & CME
/career-development/recertific...Subdomain ESMO-MORA Recertification Process and Requirements
/career-development/recertific...Subdomain CME Tests for Handbooks
/career-development/esmo-certi...Subdomain ESMO Certificate of Professional Development
/career-development/esmo-certi...Subdomain Textduplikat ESMO Advanced Courses
/career-development/esmo-certi...Subdomain Textduplikat ESMO Preceptorship Courses
/career-development/esmo-certi...Subdomain Textduplikat ESMO Webinar Series
/career-development/esmo-certi...Subdomain Textduplikat ESMO Virtual Plenaries
/career-development/jobs-in-on...Subdomain Jobs in Oncology
/career-development/women-for-...Subdomain Women for Oncology
/career-development/women-for-...Subdomain ESMO W4O Observatory
/career-development/women-for-...Subdomain W4O Hub
/career-development/women-for-...Subdomain Resource Centre
/career-development/women-for-...Subdomain W4O Sessions and Events
/career-development/leaders-ge...Subdomain Leaders Generation Programme
/career-development/leaders-ge...Subdomain Class of 2021-2022
/career-development/leaders-ge...Subdomain Class of 2016
/career-development/leaders-ge...Subdomain Class of 2017
/career-development/leaders-ge...Subdomain Class of 2018
/career-development/leaders-ge...Subdomain Class of 2019
/career-development/leaders-ge...Subdomain Leaders Generation Programme Asia
/career-development/leaders-ge...Subdomain Textduplikat Class of 2019
/career-development/leaders-ge...Subdomain Class of 2022
/career-development/travel-gra...Subdomain Travel Grants for ESMO Meetings
/career-development/about-care...Subdomain About Career Development
/scales-and-toolsSubdomain Scales and Tools
A-TITLE Scales and Tools
/scales-and-tools/esmo-guidanc...Subdomain ESMO Guidance for Reporting Oncology real-World Evidence (ESMO-GROW)
/scales-and-tools/esmo-scale-f...Subdomain ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
/scales-and-tools/esmo-mcbsSubdomain Textduplikat ESMO-MCBS
https://www.esmo.org/researchSubdomain Research
A-TITLE Research
/research/about-the-grant-schemesSubdomain About the Grant Schemes
/research/esmo-clinical-resear...Subdomain Textduplikat ESMO Clinical Research Observatory Task Force (ECRO)
/research/esmo-clinical-resear...Subdomain Acknowledgements: Rationalizing Bureaucracy
/research/esmo-clinical-resear...Subdomain Bibliography on Clinical Trial Procedures
/research/research-funding-opp...Subdomain Research Funding opportunities
/research/research-funding-opp...Subdomain ESMO Webinar: EU Research Opportunities
/research/research-funding-opp...Subdomain How to Apply For EU Grants
/research/research-funding-opp...Subdomain EU Calls for Proposals
/research/research-funding-opp...Subdomain Training and Events
/research/research-funding-opp...Subdomain Regulatory Information
/research/research-funding-opp...Subdomain Other Research Funding Opportunities
/research/research-groups-tool...Subdomain Research Groups, Tools and Database
/research/research-groups-tool...Subdomain General research groups
/research/research-groups-tool...Subdomain Cancer research groups by type
/research/research-groups-tool...Subdomain Databases
/research/research-groups-tool...Subdomain Research tools
/research/registries-studies-a...Subdomain COVID-19 and Cancer: Registries, Studies and Surveys
/research/registries-studies-a...Subdomain ESMO-CoCARE Registry
https://www.esmo.org/for-patientsSubdomain For Patients
A-TITLE Patients
/for-patients/resources-for-ca...Subdomain Resources for Patients with Cancer
/for-patients/esmo-designated-...Subdomain ESMO Designated Centres of Integrated Oncology and Palliative Care
/for-patients/esmo-designated-...Subdomain Palliative and Supportive Care Sessions at ESMO Congress 2022 Paris
/for-patients/esmo-designated-...Subdomain How to re-accredit?
/for-patients/esmo-designated-...Subdomain Textduplikat Designated Centres Working Group
/for-patients/esmo-designated-...Subdomain Palliative and Supportive Care Sessions at ESMO Congress 2023 Madrid
/for-patients/esmo-designated-...Subdomain 2023 ESMO Designated Centres
/for-patients/cancer-care-duri...Subdomain Cancer Care During the COVID-19 Pandemic
/for-patients/cancer-care-duri...Subdomain Multiple Myeloma
/for-patients/cancer-care-duri...Subdomain Melanoma
/for-patients/cancer-care-duri...Subdomain Sarcoma
/for-patients/cancer-care-duri...Subdomain Krebstherapie während der COVID-19-Pandemie
/for-patients/cancer-care-duri...Subdomain Renal Cell Carcinoma
/for-patients/cancer-care-duri...Subdomain Prostate Cancer
/for-patients/cancer-care-duri...Subdomain Pancreatic Cancer
/for-patients/cancer-care-duri...Subdomain Textduplikat Lung Cancer
/for-patients/cancer-care-duri...Subdomain Ovarian Cancer
/for-patients/cancer-care-duri...Subdomain Palliative Care Glossary
/for-patients/cancer-care-duri...Subdomain Supportive Care Glossary
/for-patients/cancer-care-duri...Subdomain Gastro-Oesophageal Cancer
/for-patients/cancer-care-duri...Subdomain Hepatocellular Carcinoma
/for-patients/cancer-care-duri...Subdomain Endometrial Cancer
/for-patients/cancer-care-duri...Subdomain Colorectal Cancer
/for-patients/cancer-care-duri...Subdomain Primary Brain Tumour
/for-patients/cancer-care-duri...Subdomain Aggressive Lymphoma Management
/for-patients/cancer-care-duri...Subdomain Textduplikat Breast Cancer
/for-patients/cancer-care-duri...Subdomain B-cell non-Hodgkin Lymphoma
/for-patients/cancer-care-duri...Subdomain Urothelial Bladder Cancer
/for-patients/cancer-care-duri...Subdomain Hodgkin Lymphoma
/for-patients/cancer-care-duri...Subdomain Cervical Cancer
/for-patients/cancer-care-duri...Subdomain Traitement du Cancer au Cours de la Pandémie de COVID-19
/for-patients/cancer-care-duri...Subdomain Le Cure per il Cancro Durante la Pandemia da COVID-19
/for-patients/cancer-care-duri...Subdomain Cuidado del cáncer durante la pandemia de COVID-19
/for-patients/cancer-care-duri...Subdomain Glossary
/for-patients/patient-advocate...Subdomain Patient Advocates Working Group
/for-patients/patient-advocacy...Subdomain Patient Advocacy Track
/for-patients/patient-guidesSubdomain Patient Guides
/for-patients/patient-guides/p...Subdomain Patient Guides by Language
/for-patients/patient-guides/b...Subdomain Bone Health in Cancer
/for-patients/patient-guides/p...Subdomain Immunotherapy Side Effects
/for-patients/patient-guides/s...Subdomain Survivorship
/for-patients/patient-guides/c...Subdomain Cancer Pain Management
/for-patients/patient-guides/p...Subdomain Personalised Cancer Medicine
/for-patients/personalised-med...Subdomain Personalised Medicine Explained
/for-patients/getting-the-most...Subdomain Getting the Most out of Your Oncologist
/for-patients/esmo-patient-eng...Subdomain ESMO Patient Engagement Summit
https://www.esmo.org/policySubdomain Policy
A-TITLE Policy
/policy/esmo-manifestoSubdomain ESMO Manifesto
/policy/policy-newsSubdomain Policy News
/policy/esmo-public-policy-com...Subdomain Public Policy Committee
/policy/patient-advocates-work...Subdomain Textduplikat Patient Advocates Working Group
/policy/cancer-medicines-commi...Subdomain Textduplikat Cancer Medicines Committee
/policy/esmo-public-policy-tra...Subdomain ESMO Public Policy Track and Special Sessions
https://www.esmo.org/newsroomSubdomain Newsroom
A-TITLE Newsroom
/newsroom/press-and-media-hubSubdomain Press and Media Hub
https://dailyreporter.esmo.org/Neues Fenster Nofollow Extern Subdomain ESMO Daily Reporter
/oncology-newsSubdomain Oncology News
A-TITLE Oncology News
/newsroom/esmo-society-updatesSubdomain ESMO Society Updates
/membership/join-esmoSubdomain Textduplikat Become a member
https://www.esmo.org/saml/loginTextduplikat Login
/meeting-calendar/esmo-immuno-...Subdomain ESMO Immuno-Oncology Congress 2024
/meeting-calendar/esmo-immuno-...Subdomain Submit your abstract
/meeting-calendar/esmo-guideli...Neues Fenster Subdomain IMG-ALT ESMO-Webinar-Series-Nasopharyngeal-Carcinoma-ESMO-EURACAN-1000x250-July
/meeting-calendar/esmo-guideli...Subdomain Nasopharyngeal Carcinoma Webinar
/meeting-calendar/esmo-guideli...Subdomain Register Now
/living-guidelines/esmo-oncoge...Neues Fenster Subdomain IMG-ALT ESMO-Clinical-Practice-Guidelines-1000x250-Oncogene-Addicted-Metastatic-Non-Small-Cell-Lung-Cancer
/living-guidelines/esmo-oncoge...Subdomain ESMO Oncogene-Addicted mNSCLC Living Guideline
/living-guidelines/esmo-oncoge...Subdomain To the Guideline
/meeting-calendar/esmo-asia-co...Subdomain ESMO Asia 2024
/meeting-calendar/esmo-asia-co...Subdomain Sign up before 4 September
/meeting-calendar/molecular-an...Subdomain Molecular Analysis for Precision Oncology Congress 2024
/meeting-calendar/molecular-an...Subdomain Submit your abstract by 23 July!
/meeting-calendar/esmo-precept...Neues Fenster Subdomain IMG-ALT ESMO-Preceptorship-Lung-Cancer-1000x1000
/meeting-calendar/esmo-precept...Subdomain ESMO Preceptorship on Lung Cancer, 15-16 November 2024, Paris, France
/meeting-calendar/esmo-precept...Subdomain Apply now!
/meeting-calendar/esmo-precept...Neues Fenster Subdomain IMG-ALT ESMO-Preceptorship-Gastric-Cancer-1000x1000
/meeting-calendar/esmo-precept...Subdomain ESMO Preceptorship Course on Gastric Cancer, 4-5 December 2024, Singapore
/meeting-calendar/esmo-precept...Subdomain Textduplikat Apply now!
/guidelines/esmo-mcbsNeues Fenster Subdomain IMG-ALT ESMO-MCBS 1000x1000
/guidelines/esmo-mcbsSubdomain Textduplikat ESMO-MCBS
/guidelines/esmo-mcbsSubdomain Discover more
https://oncologypro.esmo.org/m...Extern Subdomain July ESMO Virtual Plenary
https://oncologypro.esmo.org/m...Extern Subdomain  Watch Now
/oncology-news/development-of-...Subdomain Development of T-Cell Lymphoma After Chimeric Antigen Receptor T-Cell Therapy
/oncology-news/ema-recommends-...Subdomain EMA Recommends Granting a Conditional Marketing Authorisation for Odronextamab
/oncology-news/entrectinib-is-...Subdomain Entrectinib Is Effective and Well Tolerated in Patients with Treatment-Naïve ROS1-positive Advanced/Metastatic NSCLC
/oncology-news/fda-approves-du...Subdomain FDA Approves Durvalumab with Chemotherapy for Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer
https://dailyreporter.esmo.org...Extern Subdomain First-line avimantamab plus lazertinib shows efficacy in patients with high-risk EGFR-mutant advanced NSCLC
/oncology-news/one-year-of-adj...Subdomain One Year of Adjuvant T-DM1 Leads to Outstanding Long-Term Outcomes Among Patients with Stage I HER2-positive Breast Cancer
/for-patients/patient-guides/b...Subdomain Patient Guide in Bladder Cancer Now Available Also in Greek
/oncology-news/ema-recommends-...Subdomain EMA Recommends Extension of Therapeutic Indications for Olaparib to Patients with Endometrial Cancer
/oncology-news/pet-2-guided-br...Subdomain PET-2-Guided BrECADD Better Tolerated and More Effective than eBEACOPP in Patients with Newly Diagnosed, Advanced-Stage cHL
/oncology-newsSubdomain More Oncology News
/newsroom/press-and-media-hub/...Subdomain More Press Releases
/newsroom/esmo-society-updatesSubdomain More Society Updates
https://dailyreporter.esmo.org/Neues Fenster Extern Subdomain Read the ESMO Daily Reporter
/oncology-news/development-of-...Subdomain Textduplikat Development of T-Cell Lymphoma After Chimeric Antigen Receptor T-Cell Therapy
/oncology-news/ema-recommends-...Subdomain Textduplikat EMA Recommends Granting a Conditional Marketing Authorisation for Odronextamab
/oncology-news/entrectinib-is-...Subdomain Textduplikat Entrectinib Is Effective and Well Tolerated in Patients with Treatment-Naïve ROS1-positive Advanced/Metastatic NSCLC
/oncology-news/fda-approves-du...Subdomain Textduplikat FDA Approves Durvalumab with Chemotherapy for Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer
/oncology-news/one-year-of-adj...Subdomain Textduplikat One Year of Adjuvant T-DM1 Leads to Outstanding Long-Term Outcomes Among Patients with Stage I HER2-positive Breast Cancer
/oncology-news/ema-recommends-...Subdomain Textduplikat EMA Recommends Extension of Therapeutic Indications for Olaparib to Patients with Endometrial Cancer
/oncology-news/pet-2-guided-br...Subdomain Textduplikat PET-2-Guided BrECADD Better Tolerated and More Effective than eBEACOPP in Patients with Newly Diagnosed, Advanced-Stage cHL
/oncology-news/fda-grants-acce...Subdomain FDA Grants Accelerated Approval to Adagrasib with Cetuximab for KRAS G12C-mutated Advanced Colorectal Cancer
/oncology-news/second-or-third...Subdomain Second- or Third-Line Treatment with Tisotumab Vedotin Results in Greater Efficacy than Chemotherapy in Patients with Recurrent Cervical Cancer
/oncology-newsSubdomain Textduplikat More Oncology News
/newsroom/press-and-media-hub/...Subdomain Prevention and Early Detection of Gastrointestinal Cancers Take on New Importance Amidst a Younger Population
/newsroom/press-and-media-hub/...Subdomain Cross-Border Network of European Specialists Provides New Treatment Options For Women with Complex Rare Gynaecological Cancers
/newsroom/press-and-media-hub/...Subdomain ESMO Gastrointestinal Cancers Congress 2024 Munich, Germany, 26-29 June
/newsroom/press-and-media-hub/...Subdomain ESMO Gynaecological Cancers Congress 2024, 20-22 June, Florence, Italy
/newsroom/press-and-media-hub/...Subdomain World No Tobacco Day 2024: European Societies call for an EU Endgame on Tobacco
/newsroom/press-and-media-hub/...Subdomain Assisted Reproduction Treatments are Safe in Young Breast Cancer Survivors with High-risk Genes
/newsroom/press-and-media-hub/...Subdomain ESMO Breast Cancer 2024, 15-17 May, Berlin, Germany
/newsroom/press-and-media-hub/...Subdomain European Lung Cancer Congress 2024, 20-23 March, Prague, Czech Republic
/newsroom/press-and-media-hub/...Subdomain ESMO Sarcoma and Rare Cancers Congress 2024, 14-16 March, Lugano, Switzerland
/newsroom/press-and-media-hub/...Subdomain Textduplikat More Press Releases
/newsroom/esmo-society-updates...Subdomain ESMO Calls for Urgent Action at Both EU and National Levels to Safeguard the Future of Oncological Research in Europe
/newsroom/esmo-society-updates...Subdomain ESMO Journals Have Maintained Strong Impact Factors
/newsroom/esmo-society-updates...Subdomain New ESMO President 2027-2028 Elected
/newsroom/esmo-society-updates...Subdomain Three Prominent ESMO Officers Shine in News Pages for Their Accomplishments in Cancer Research
/newsroom/esmo-society-updates...Subdomain Medical Oncologists Incredulous at the Commission’s Latest Backtracking on the Evaluation of the EU Tobacco Products Directive
/newsroom/esmo-society-updates...Subdomain 2024 ESMO Breast Cancer Award Recipient Announced
/newsroom/esmo-society-updates...Subdomain 2024 Heine H. Hansen Award Recipient Announced
/newsroom/esmo-society-updates...Subdomain Nomination Process for the 2024 ESMO Society Awards Now Open 
/newsroom/esmo-society-updates...Subdomain ESMO Committees and Working Groups: New Chair Appointments
/newsroom/esmo-society-updatesSubdomain Textduplikat More Society Updates
https://dailyreporter.esmo.org...Extern Subdomain Textduplikat First-line avimantamab plus lazertinib shows efficacy in patients with high-risk EGFR-mutant advanced NSCLC
https://dailyreporter.esmo.org...Extern Subdomain Eftilagimod alpha plus pembrolizumab shows promise in HNSCC with negative PD-1 expression
https://dailyreporter.esmo.org...Extern Subdomain How to interpret genomic testing results? ESMO recommendations to make reports easy to read
https://dailyreporter.esmo.org...Extern Subdomain Oncologists do not feel well-prepared to address the health needs of LGBTQ cancer patients
https://dailyreporter.esmo.org...Extern Subdomain Doublet immunotherapy consolidates its role in hepatocellular carcinoma
https://dailyreporter.esmo.org...Extern Subdomain Ten years of improvement in the treatment of liver cancer
https://dailyreporter.esmo.org...Extern Subdomain Growing evidence supports the use of ctDNA as a biomarker in colon cancer
https://dailyreporter.esmo.org...Extern Subdomain Harnessing the power of the gut microbiome in colorectal cancer
https://dailyreporter.esmo.org...Extern Subdomain Liver transplantation plus chemotherapy prolongs survival in patients with definitively unresectable colorectal liver metastases
https://dailyreporter.esmo.org/Neues Fenster Extern Subdomain Textduplikat Read the ESMO Daily Reporter
https://www.esmo.org/guidelinesNeues Fenster Subdomain IMG-ALT Provide your patients with the best care options.
https://www.esmo.org/guidelinesSubdomain Textduplikat Provide your patients with the best care options.
https://www.esmo.org/guidelinesSubdomain Read the guidelines
/about-esmo-meetings/esmo-prec...Subdomain Preceptorships
/about-esmo-meetings/esmo-cour...Subdomain Courses on Medical Oncology for Medical Students
/about-esmo-meetings/esmo-adva...Subdomain Advanced Courses
/about-esmo-meetings/esmo-summitsSubdomain Summits
/about-esmo/discover-esmo-jour...Neues Fenster Subdomain IMG-ALT ESMO Oncology Journals
/about-esmo/discover-esmo-jour...Subdomain Textduplikat ESMO Oncology Journals
/about-esmo/discover-esmo-jour...Subdomain Textduplikat Annals of Oncology
/about-esmo/discover-esmo-jour...Subdomain Textduplikat ESMO Open
/about-esmo/discover-esmo-jour...Subdomain ESMO IO Tech
/about-esmo/discover-esmo-jour...Subdomain More about Journals
https://oncologypro.esmo.org/e...Neues Fenster Extern Subdomain IMG-ALT Publications
https://oncologypro.esmo.org/e...Extern Subdomain Textduplikat Publications
https://oncologypro.esmo.org/e...Neues Fenster Extern Subdomain Essentials for Clinicians
https://oncologypro.esmo.org/e...Neues Fenster Extern Subdomain Handbooks
https://oncologypro.esmo.org/e...Neues Fenster Extern Subdomain Factsheet on Biomarkers
https://oncologypro.esmo.org/e...Neues Fenster Extern Subdomain Visit the Education library
/meeting-calendar/esmo-course-...Subdomain IMG-ALT ESMO-Medical-Student-Course-Valencia-2024-1000x1000
/meeting-calendar/esmo-course-...Subdomain ESMO Course in Medical Oncology for Medical Students Valencia 2024
/meeting-calendar/esmo-precept...Subdomain IMG-ALT ESMO-Preceptorship-Breast-Cancer-1000x1000
/meeting-calendar/esmo-precept...Subdomain ESMO Preceptorship on Breast Cancer 2024: Munich
/meeting-calendar/esmo-academy...Subdomain IMG-ALT ESMO-Academy-Meeting-2024-1000x1000
/meeting-calendar/esmo-academy...Subdomain ESMO Academy 2024
/meeting-calendar/esmo-course-...Subdomain IMG-ALT ESMO-Medical-Student-Course-Naples-2024-1000x1000
/meeting-calendar/esmo-course-...Subdomain ESMO Course in Medical Oncology for Medical Students Naples 2024
/meeting-calendar/esmo-advance...Subdomain IMG-ALT ESMO-Advanced-Courses-Breast-Cancer-1000x1000
/meeting-calendar/esmo-advance...Subdomain ESMO Advanced Course on Role of CDK4/6 Inhibitors in Hormone Receptor Positive HER2 Negative in Breast Cancer 2024: Jeddah
/meeting-calendar/esmo-congres...Subdomain IMG-ALT ESMO-Congress-2024-1000x1000
/meeting-calendar/esmo-congres...Subdomain ESMO Congress 2024
/meeting-calendar/esmo-precept...Subdomain IMG-ALT ESMO-Preceptorship-Ovarian-Cancer-2024-1000x1000
/meeting-calendar/esmo-precept...Subdomain ESMO Preceptorship on Ovarian Cancer 2024: Lisbon
/meeting-calendar/esmo-precept...Subdomain Textduplikat IMG-ALT ESMO-Preceptorship-Gastric-Cancer-1000x1000
/meeting-calendar/esmo-precept...Subdomain ESMO Preceptorship on Gastric Cancer 2024: Lisbon
/meeting-calendar/esmo-precept...Subdomain IMG-ALT ESMO-Preceptorship-Molecular Cancer Biology-1000x1000
/meeting-calendar/esmo-precept...Subdomain ESMO Preceptorship on Practising Oncology: Dealing with Special Strategies, Patient Populations and Toxicities 2024: Lugano
/meeting-calendar/esmo-advance...Subdomain IMG-ALT ESMO-Advanced-Courses-ADC-1000x1000
/meeting-calendar/esmo-advance...Subdomain ESMO Advanced Course on ADC Development, Therapeutic Applications and Research: Breast, Gynaecological and GI Cancers 2024: Zurich
/meeting-calendar/esmo-advance...Subdomain Textduplikat IMG-ALT ESMO-Advanced-Courses-ADC-1000x1000
/meeting-calendar/esmo-advance...Subdomain ESMO Advanced Course on ADC Development, Therapeutic Applications and Research: Thoracic and GU Cancers 2024: Singapore
/meeting-calendar/esmo-advance...Subdomain Textduplikat IMG-ALT ESMO-Advanced-Courses-ADC-1000x1000
/meeting-calendar/esmo-advance...Subdomain ESMO Advanced Course on ADC Development, Therapeutic Applications and Research: Breast, Gynaecological and GI Cancers 2024: Singapore
/meeting-calendarSubdomain Discover all ESMO meetings
https://www.youtube.com/user/E...Extern Subdomain Watch all ESMO videos
/career-development/oncology-f...Subdomain Are you looking for a fellowship not offered by ESMO or would like to post a fellowship?
/career-development/oncology-f...Subdomain External Fellowship
/career-development/esmo-exami...Subdomain Textduplikat ESMO Examination
/career-development/esmo-exami...Subdomain Trivialer Linktext
Read more
/career-development/oncology-f...Subdomain Thinking of applying for an ESMO Oncology Fellowship?
/career-development/oncology-f...Subdomain Fellowship Programme
/membership/member-benefitsSubdomain Discover member benefits
https://www.esmo.org/terms-of-useSubdomain Terms of Use
/terms-of-use/privacy-policySubdomain Privacy Policy
https://www.esmo.org/about-esmoSubdomain Textduplikat About ESMO
/about-esmo/contact-usSubdomain Textduplikat Contact Us
https://esmo.my.site.com/myesm...Extern Subdomain Login to your ESMO account
https://www.twitter.com/myesmoNeues Fenster Extern Subdomain Twitter
https://www.facebook.com/esmo.orgNeues Fenster Extern Subdomain Facebook
https://www.youtube.com/user/E...Neues Fenster Extern Subdomain Youtube
/rss/feed/esmo-newsSubdomain RSS
https://www.linkedin.com/compa...Neues Fenster Extern Subdomain LinkedIn
https://www.instagram.com/esmo...Neues Fenster Extern Subdomain Instagram
https://www.esmo.org/Anchor Kein Text
/terms-of-use/privacy-policyNeues Fenster Subdomain Textduplikat Privacy Policy

Serverkonfiguration

HTTP-Weiterleitungen
(Extrem wichtig)
Die Seite leitet weiter auf "https://www.esmo.org/"
HTTP-Header
(Wichtig)
Es wird kein X-Powered HTTP-Header mitgesendet.
Der Webserver nutzt GZip zur komprimierten Übertragung der Webseite (HTML).
Performance
(Wenig wichtig)
Die Antwortzeit der HTML-Seite ist mit 0,10 Sekunden unter der Zielmarke von 0,40 Sekunden.
Die Dateigröße des HTML-Dokuments ist mit 340 kB in Ordnung.

HTTP-Header

NameWert
content-typetext/html; charset=UTF-8
dateMon, 22 Jul 2024 08:56:20 GMT
content-encodinggzip
x-varnish316704387 314342048
age164
varyAccept-Encoding
cache-controlprivate, no-cache, no-store, must-revalidate
accept-rangesbytes
strict-transport-securitymax-age=16000000; preload;
statuscode200
http_versionHTTP/2

Externe Faktoren

Blacklists
(Nice to have)
Die Seite wird nicht als "nur für Erwachsene" eingestuft.
Die Seite wird von Wikipedia verlinkt.
Die Seite ist exzellent von anderen Webseiten verlinkt.
Die Seite hat Backlinks von 5.683 verweisenden Domains.
Die Seite hat insgesamt 902.116 Backlinks.
Die Seite hat Backlinks von 4.083 verschiedenen IP Adressen.
Verbreitung bei Facebook
(Wenig wichtig)
Die Seite hat 0 Shares und Kommentare auf Facebook.

Links von Wikipedia

Mehr Links findest Du mit der Wikipedia-Suche

Robots.txt

User-agent: *
Crawl-delay: 5
Disallow: /content/search
Disallow: /search
Disallow: /user/login
Disallow: /user/logout
Disallow: /login
Disallow: /logout
Disallow: /saml/
Disallow: /layout/
Disallow: /nglayouts/ajax/
Disallow: /myesmo/
Disallow: /Function/
Disallow: /Event-Type/
Disallow: /Term/
Disallow: /Promoted-content/
Disallow: /view-news/
Disallow: /resources/
Disallow: /useful-links/
Disallow: /no_cache/
Disallow: /fileadmin/
Disallow: /events/
Disallow: /education-research/
Disallow: /career-grants/
Disallow: /Helpdesk-Categories
Disallow: /ESMO-Members-Forum
Disallow: /Featured-articles
Disallow: /Links
Disallow: /Tests
Disallow: /_deprecated/
Disallow: /_tagging-objects/
Disallow: /_old-structure/
Disallow: /daily_reporter/
Disallow: /living-guidelines/
Disallow: /esp/
Disallow: /attendances/certificate/
Sitemap: https://www.esmo.org/sitemaps/index

User-agent: MJ12bot
Disallow: /

User-agent: AhrefsBot
Disallow: /

Ähnliche Seiten

Suchvorschau

www.esmo.org
European Society for Medical Oncology
ESMO is Europe’s leading medical oncology society, providing a professional network for its members and working with national societies across Europe.

Wichtigste Suchbegriffe

Folgende Keywords wurden erkannt. Überprüfe die Optimierung dieser Keywords für Deine Seite.

KeywordErgebnisPrüfen
Oncology81%Check
Medical81%Check
Medical Oncology81%Check
Society Medical79%Check
Society77%Check
Europe77%Check
European Society72%Check
ESMO Oncology67%Check
European66%Check
ESMO Society65%Check
Weitere Keywords anzeigen

Analysiere jetzt kostenlos bis zu 1.000 Unterseiten von esmo.org!

Kostenlos Testen
Die Nutzung des Basis Accounts ist zeitlich unbegrenzt möglich

Cookie Einstellungen

Wir verwenden Cookies, damit unsere Website funktioniert und auch für Analyse- und Werbezwecke. Du kannst optionale Cookies selbstverständlich auch deaktivieren, siehe die folgenden Links für weitere Informationen.

Impressum | Datenschutz

Diese Cookies werden für grundlegende Websitefunktionen benötigt.

Damit wir besser verstehen, wie Besucher unsere Website nutzen.

Damit wir für Dich passgenaue Angebote bereitstellen können.